CEP-18770 (Delanzomib)
目录号: A11145
Proteasome 抑制剂
CEP-18770 是一种新型口服活性蛋白酶体抑制剂,具有良好的肿瘤选择性特征,适用于治疗 MM(多发性骨髓瘤)和其他对蛋白酶体抑制敏感的恶性肿瘤。
| Discription | CEP-18770 is a novel orally active proteasome inhibitor with a favorable tumor selectivity profile for the treatment of MM and other malignancies responsive to proteasome inhibition. | ||
|---|---|---|---|
| Targets |
|
| 目录号 | A11145 |
|---|---|
| 分子式 | C21H28BN3O5 |
| 分子量 | 413.3 |
| CAS号 | 847499-27-8 |
| SMILES | B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O |
| 其他名称 | CEP18770 |
| 储存条件 | Store lyophilized at -20ºC, keep desiccated. |
| In vitro | DMSO | 73 mg/mL (176.63 mM) | |
| Water | Insoluble | ||
| Ethanol | 73 mg/mL (176.63 mM) | ||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 24.2 mL | 120.98 mL | 241.95 mL |
| 0.5 mM | 4.84 mL | 24.2 mL | 48.39 mL |
| 1 mM | 2.42 mL | 12.1 mL | 24.2 mL |
| 5 mM | 0.48 mL | 2.42 mL | 4.84 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2